Shots:
- Rose received exclusive global rights to MannKind’s Technosphere tech to develop & commercialize ROSE-010 Technosphere, a rapid-acting GLP-1 receptor agonist, with initial work focused on formulation re-establishment & optimization, followed by nonclinical & regulatory development
- MannKind will receive equity in Rose Pharma, the right to receive royalties on potential future net sales & board representation, while Rose Pharma retains responsibility for clinical development, regulatory strategy & commercialization; financial terms were undisclosed
- MannKind will provide formulation development & manufacturing support for ROSE-010 Technosphere through completion of the P-Ib trial in weight-management
Ref: Globenewswire | Image: Mannkind & Rose Pharma | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
